Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
55513-0094-91 55513-0094 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Sep 25, 2006 Feb 28, 2009 No Longer Used
55513-0046-04 55513-0046 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Jul 23, 2003 Apr 30, 2009 No Longer Used
55513-0046-01 55513-0046 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Feb 18, 2011 Apr 30, 2009 No Longer Used
55513-0044-04 55513-0044 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Jul 23, 2003 Feb 28, 2009 No Longer Used
55513-0041-01 55513-0041 Darbepoetin alfa Aranesp Ancillary Therapy Erythropoiesis-Stimulating Agent Feb 18, 2011 Feb 28, 2009 No Longer Used
55513-0032-01 55513-0032 Darbepoetin alfa Aranesp 500.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Jun 7, 2006 In Use
57894-0505-05 57894-0505 Daratumumab Darzalex IV 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Oct 15, 2021 In Use
57894-0502-20 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov 16, 2015 Nov 30, 2026 In Use
57894-0502-05 57894-0502 Daratumumab Darzalex 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Nov 16, 2015 Oct 31, 2026 In Use
57894-0505-20 57894-0505 Daratumumab Darzalex IV 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Oct 15, 2021 In Use
57894-0503-01 57894-0503 Daratumumab and hyaluronidase-fihj (human recombinant) Darzalex Faspro 1800.0 mg/15mL, 4.9 mg/15mL, 18.4 mg/15mL, 30000.0 U/15mL, 13.5 mg/15mL, 6.0 mg/15mL, 735.1 mg/15mL Immunotherapy Monoclonal Antibody CD38 Subcutaneous May 1, 2020 In Use
66993-0489-35 66993-0489 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Dec 4, 2017 Nov 30, 2024 In Use
55150-0928-02 55150-0928 DACTINOMYCIN DACTINOMYCIN 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Mar 15, 2021 In Use
67457-0513-05 67457-0513 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Jan 1, 2018 In Use
55292-0811-55 55292-0811 Dactinomycin Cosmegen 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Dec 10, 1964 Nov 30, 2024 In Use
55150-0431-01 55150-0431 DACTINOMYCIN DACTINOMYCIN 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Mar 15, 2021 In Use
39822-2100-02 39822-2100 dactinomycin dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Jul 31, 2019 In Use
42658-0008-01 42658-0008 Dactinomycin Dactinomycin 0.5 mg/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous May 8, 2024 In Use
67457-0513-99 67457-0513 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Jan 1, 2018 In Use
71288-0129-02 71288-0129 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Nov 13, 2020 In Use
67457-0928-02 67457-0928 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Jun 20, 2019 In Use
67386-0811-55 67386-0811 Dactinomycin Cosmegen Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Dec 10, 1964 Apr 23, 2013 No Longer Used
00069-2299-30 00069-2299 dacomitinib Vizimpro 45.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 In Use
00069-1198-30 00069-1198 dacomitinib Vizimpro 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 In Use
63539-0197-90 63539-0197 Dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb 1, 2019 In Use

Found 11120 results — Export these results